TICKERNERD
Menu
FBRXFBRXHealthcare · Biotechnology

FBRX Stock Forecast: Forte Biosciences, Inc. Price Predictions for 2026-2027

Last close, 12 Aug 2026
$77
−0.12% on the day

The 5 Wall Street analysts covering Forte Biosciences, Inc. hold a median 12-month price target of $77 — +0.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 12 Aug 2026 — in the lower half.

Market cap
$1.6B
Ticker Nerd rank
40 / 100
Median analyst target
$77
Analysts covering
5
Total return, dividends reinvested
1W
+0.2%
1M
+74.8%
YTD
+181.6%
1Y
+613.6%
From 52W high
−0.3%
From 52W low
+645.4%
$10
$77
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FBRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Forte Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Aug 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Accruals
71
Value
63
Size
40
Revisions
40
Growth
39
Volatility
38
Issuance
26
Quality
14

Momentum (100): The shares have been drifting up relative to others.

Quality (14): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FBRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FBRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26FBRXHigh $77Median $77Low $61

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
1 Buy4 Hold0 Sell
Low $61Median $77High $77

The green dot is the last close — the median target sits +0.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 July 2026BarclaysDowngradeEqual-Weight$74 → $77
21 July 2026BarclaysInitiatesOverweight$74
25 Nov 2025Evercore ISI GroupInitiatesOutperform$65
25 Nov 2025Evercore ISI GroupInitiatesOutperform—
17 Nov 2025Chardan CapitalMaintainsBuy—
18 Aug 2025GuggenheimInitiatesBuy—
15 Aug 2025Chardan CapitalMaintainsBuy—
24 June 2025Chardan CapitalMaintainsBuy—
1 Apr 2025Chardan CapitalMaintainsBuy—
21 Jan 2025TD CowenInitiatesBuy—
4 Dec 2024Chardan CapitalMaintainsBuy—
15 Nov 2024Chardan CapitalMaintainsBuy—
19 Aug 2024Chardan CapitalMaintainsBuy—
30 May 2024Brookline CapitalInitiatesBuy—
8 Apr 2024Ladenburg ThalmannUpgradeBuy—
20 Sept 2021Chardan CapitalUpgradeNeutral—
3 Sept 2021B. Riley SecuritiesDowngradeNeutral—
3 Sept 2021Brookline CapitalDowngradeHold—
3 Sept 2021Chardan CapitalDowngradeSell—
3 Sept 2021Ladenburg ThalmannDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FBRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

FBRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
1
Fundamentals

Forte Biosciences, Inc. (FBRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−16.3×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
32.6×

Cheaper than 3% of US stocks

EV / EBITDA
−23.7×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−188.4%

Higher than 7% of US stocks

Return on assets
−83.9%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

FBRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FBRXForte Biosciences, Inc.$1.6B
40
TYRATyra Biosciences, Inc.$1.5B
32
VIRVir Biotechnology, Inc.$1.5B
90
SLBTSL Science Holding Ltd.$1.5B
0
MAZEMaze Therapeutics, Inc.$1.5B
18
MRVIMaravai Lifesciences Holdings, Inc.$1.5B
88
JBIOJade Biosciences, Inc.$1.5B
26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Forte Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FBRX news & analysis

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

Business Wire · 11 Aug 2026negative

Kahn Swick & Foti, LLC, a law firm led by former Louisiana Attorney General Charles C. Foti Jr., has launched an investigation into the proposed sale of Forte Biosciences to argenx SE. Under the deal's terms, Forte shareholders would receive $77.00 in cash per share, and KSF is examining whether that consideration and the process leading to it were adequate.

Why it matters — A law firm is investigating the adequacy of the sale price and process, which could raise questions about the proposed acquisition for FBRX shareholders.

FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders

Business Wire · 8 Aug 2026negative

Halper Sadeh LLC, an investor rights law firm, is investigating whether Forte Biosciences and its board violated federal law in connection with the company's sale to argenx for $77.00 per share in cash. The firm is encouraging Forte shareholders to learn about their rights and options regarding the transaction.

Why it matters — A shareholder-rights investigation raises potential legal scrutiny over the fairness of Forte's acquisition price for shareholders.

Alger Small Cap Focus Fund Q2 2026 Portfolio Review

Seeking Alpha · 6 Aug 2026negative

Alger Small Cap Focus Fund's Q2 2026 portfolio review identified Forte Biosciences Inc. as one of the top detractors from performance during the quarter, alongside Karman Holdings and GeneDx Holdings. The review also named Nebius Group, Credo Technology Group, and Guardant Health among the top contributors.

Why it matters — FBRX watchers would care because its inclusion among the fund's top performance detractors signals weak relative performance during the quarter.

Halper Sadeh LLC is Investigating Whether FBRX and SAFT are Obtaining Fair Deals for their Shareholders

GlobeNewsWire · 29 July 2026negative

Halper Sadeh LLC is investigating whether the proposed transactions involving Forte Biosciences, Inc. (FBRX) and SAFT provide fair treatment to all shareholders, noting that insiders may receive substantial financial benefits not available to ordinary shareholders.

Why it matters — FBRX shareholders should be aware that an investigation has been opened into whether the deal terms unfairly favor insiders and may limit the ability to consider better competing offers.

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

Business Wire · 28 July 2026negative

Law firm Kahn Swick & Foti is investigating the proposed sale of Forte Biosciences to argenx SE, specifically examining whether the $77-per-share cash consideration and the sale process are adequate for shareholders.

Why it matters — The investigation could lead to legal challenges or changes to the merger terms, potentially affecting the value FBRX shareholders ultimately receive.

FAQ

Frequently asked questions about FBRX stock

What is the FBRX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Forte Biosciences, Inc. have a median 12-month price target of $77, with estimates ranging from $61 to $77. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FBRX stock a buy right now?

Of the 5 analysts covering Forte Biosciences, Inc., 1 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Forte Biosciences, Inc. 40 out of 100 across roughly 4,600 US stocks as at 12 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FBRX?

As at 12 Aug 2026, Forte Biosciences, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will FBRX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +0.3% from the last close, and Ticker Nerd's factor model ranks Forte Biosciences, Inc. 40 out of 100 as at 12 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FBRX stock forecast for 2030?

No analyst covering Forte Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FBRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $61 to $77 over the next 12 months.

How has FBRX stock performed over the past year?

Forte Biosciences, Inc. returned +613.6% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Forte Biosciences, Inc. do?

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and autoimmune-related diseases.

What is the latest news on FBRX?

The most recent item we track (Business Wire, 11 Aug 2026): "Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX". Kahn Swick & Foti, LLC, a law firm led by former Louisiana Attorney General Charles C. Foti Jr., has launched an investigation into the proposed sale of Forte Biosciences to argenx SE. Under the deal's terms, Forte shareholders would receive $77.00 in cash per share, and KSF is examining whether that consideration and the process leading to it were adequate.

Company

About Forte Biosciences, Inc.

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and autoimmune-related diseases. The company’s core activity today centers on advancing FB-102, a proprietary anti-CD122 monoclonal antibody designed to modulate immune pathways implicated in conditions such as graft-versus-host disease, vitiligo, alopecia areata, celiac disease, and type 1 diabetes. Operating within the biotechnology and pharmaceutical preparations sectors, Forte Biosciences targets areas of high unmet medical need, aiming to address complex, immune-driven disorders with targeted biologic interventions. Its development programs are currently in preclinical and early clinical stages, placing the company firmly in the clinical-stage category with no commercialized products yet. Forte Biosciences is headquartered in Dallas, Texas, United States, where it concentrates research, development, and corporate functions. By focusing on novel antibody-based treatments for systemic autoimmune conditions, Forte Biosciences plays a specialized role in the healthcare market as an innovator in immune-modulating therapeutics.

CEO Dr. Paul A. Wagner Ph.D. · 22 employees · United States · https://www.fortebiorx.com